Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.
Samsung Biologics has integrated Solentim’s VIPS single cell seeding platform and Cell Metric CLD platform to its R&D facility in San Francisco, CA. These instruments are designed for single-cell cloning and can ensure monoclonality to increase the speed and efficiency of master cell bank development.
With the additions, Samsung’s San Francisco R&D facility can offer rapid, high quality development services, including cell line development. Solentim’s VIPS and Cell Metric CLD instruments will be used in conjunction with Samsung Biologics’ recently launched proprietary cell line platform, S-CHOice, which Samsung Biologics debuted in September 2020. The VIPS and Cell Metric CLD platforms were added in October 2020.
“We’re pleased to extend our long-standing partnership with Samsung Biologics, which has previously purchased and enjoyed success with our equipment in its headquarter operations,” said Mark Truesdale, CEO of Solentim, in an Oct. 7, 2020 company press release.
Source: Solentim
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.